Bills · HR 7877
IN COMMITTEE· 119TH CONGRESS
House BillHR 7877Health
Shane DiGiovanna Act
INTRO MAR 9· LAST ACTION MAR 17
READING
2MIN
COSPONSORS
5
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenThis bill matters because it addresses a significant challenge faced by individuals with Epidermolysis Bullosa (EB), a rare and devastating genetic skin condition. People with EB often require extensive and continuous wound care, which can be incredibly expensive and difficult to manage, leading to poor health outcomes and frequent hospitalizations if not properly treated. Currently, Medicaid coverage for these essential treatments can be inconsistent across states, creating disparities in care.
If this bill becomes law, it would ensure that for two years, all Medicaid beneficiaries with EB nationwide have access to a specific range of crucial wound care treatments and supplies. This could drastically improve their quality of life, reduce pain, prevent infections, and potentially decrease hospital visits, leading to better health. The findings from this demonstration program will provide valuable data that could inform future permanent policy changes, ensuring more consistent and comprehensive care for this vulnerable population.
KEY PROVISIONS
4AI-extractedPROVISION 01
Establishes a 2-year demonstration program under the Medicaid program to test mandatory coverage for specific wound care treatments for Epidermolysis Bullosa (EB).
This aims to understand the real-world impact of requiring consistent wound care coverage for EB patients across all state Medicaid programs.
PROVISION 02
Requires coverage for a defined list of items and services, including over-the-counter medications, antiseptics, antibiotic ointments, and essential wound care supplies like dressings and gauze.
This ensures that a comprehensive set of necessary treatments and supplies are accessible to EB patients, rather than leaving coverage decisions open to interpretation.
PROVISION 03
Mandates that the demonstration program be conducted on a nationwide basis.
This ensures that the test program gathers data from a diverse set of patients and healthcare systems across all states, providing a robust dataset for evaluation.
PROVISION 04
Requires the Secretary of HHS to submit a report to Congress one year after the program concludes, evaluating expenditures, health outcomes, and recommendations for preventing hospitalizations.
This report is crucial for informing future legislative decisions about permanent Medicaid coverage for EB, ensuring policy is data-driven.
SPONSORSHIP
1 + 5
D· Ohio
YRS IN OFFICE
3
BILLS LED
32
COSPONSOR BREAKDOWNBIPARTISAN · 0%
DEM 5 REP 0 IND 0
ACTION TIMELINE
3 EVENTSMAR 17
Sponsor introductory remarks on measure. (CR H2535)
MAR 9
Introduced in House
MAR 9
Referred to the House Committee on Energy and Commerce.
BILL INFO
TypeHouse Bill
NumberHR 7877
Congress119th
StatusIn Committee
IntroducedMar 9, 2026
Last actionMar 17, 2026
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
IN COMMITTEE· 119TH CONGRESS · ENERGY AND COMMERCE COMMITTEE · INTRODUCED MAR 9, 2026
House BillHR 7877Health
Shane DiGiovanna Act
INTRODUCED MAR 9, 2026· LAST ACTION MAR 17, 2026
PASSAGE CHANCES
—%
READING
2 min
COSPONSORS
5
COMPLEXITY
Moderate
